<?xml version="1.0" encoding="ISO-8859-1"?><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<front>
<journal-meta>
<journal-id>1699-714X</journal-id>
<journal-title><![CDATA[Revista de la OFIL ]]></journal-title>
<abbrev-journal-title><![CDATA[Rev. OFIL·ILAPHAR]]></abbrev-journal-title>
<issn>1699-714X</issn>
<publisher>
<publisher-name><![CDATA[Organización de Farmacéuticos Ibero-Latinoamericanos]]></publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id>S1699-714X2020000300240</article-id>
<article-id pub-id-type="doi">10.4321/s1699-714x2020000300015</article-id>
<title-group>
<article-title xml:lang="es"><![CDATA[Estado actual de los medicamentos con fentanilo en España]]></article-title>
<article-title xml:lang="en"><![CDATA[Current situation of different fentanyl delivery systems in Spain]]></article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Holgado]]></surname>
<given-names><![CDATA[MA]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Candil-Recio]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
</contrib-group>
<aff id="Af1">
<institution><![CDATA[,Universidad de Sevilla Facultad de Farmacia Departamento de Farmacia y Tecnología Farmacéutica]]></institution>
<addr-line><![CDATA[ ]]></addr-line>
<country>España</country>
</aff>
<pub-date pub-type="pub">
<day>00</day>
<month>09</month>
<year>2020</year>
</pub-date>
<pub-date pub-type="epub">
<day>00</day>
<month>09</month>
<year>2020</year>
</pub-date>
<volume>30</volume>
<numero>3</numero>
<fpage>240</fpage>
<lpage>250</lpage>
<copyright-statement/>
<copyright-year/>
<self-uri xlink:href="http://scielo.isciii.es/scielo.php?script=sci_arttext&amp;pid=S1699-714X2020000300240&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://scielo.isciii.es/scielo.php?script=sci_abstract&amp;pid=S1699-714X2020000300240&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://scielo.isciii.es/scielo.php?script=sci_pdf&amp;pid=S1699-714X2020000300240&amp;lng=en&amp;nrm=iso"></self-uri><abstract abstract-type="short" xml:lang="es"><p><![CDATA[RESUMEN El dolor es una de las principales consultas que se realiza en Atención Primaria, siendo uno de los síntomas más prevalentes en los pacientes con cáncer. Es fundamental su correcto diagnóstico y la elección de un medicamento adecuado a cada tipo de dolor. El fentanilo es un analgésico opioide ampliamente utilizado para el tratamiento del dolor intenso. Está disponible en varias formas farmacéuticas para distintas vías de administración. Las formas farmacéuticas de liberación inmediata se usan para el tratamiento del dolor irruptivo oncológico porque este tipo de dolor es de aparición súbita, intenso y de corta duración, por lo que se requiere un medicamento de inicio rápido y corta acción. Estas formas farmacéuticas son de absorción transmucosa (oral y nasal), ya que esta vía permite una absorción rápida del fármaco y una elevada biodisponibilidad. Las formas farmacéuticas con las que se puede conseguir este rápido efecto son: comprimidos para chupar con aplicador bucal integrado, comprimidos bucales y sublinguales, películas bucales y preparados intranasales. Hay que resaltar, que estos medicamentos, aunque contienen el mismo principio activo, presentan diferencias en sus perfiles farmacocinéticos, por lo que no son intercambiables. Por otro lado, las formas de liberación controlada de fentanilo comercializadas actualmente son los parches transdérmicos. Estos se usan para el tratamiento del dolor crónico o basal ya que permiten mantener niveles plasmáticos constantes del fármaco.]]></p></abstract>
<abstract abstract-type="short" xml:lang="en"><p><![CDATA[SUMMARY Pain is one of the main consultations carried out in Primary Care, being one of the most prevalent symptoms in cancer patients. Its correct diagnosis and the choice of a suitable medication for each type of pain are essential. Fentanyl is an opioid analgesic widely used for the treatment of severe pain. It is available in various pharmaceutical forms for different routes of administration. Pharmaceutical forms of immediate release are used for the treatment of breakthrough cancer pain because this type of pain is sudden, intense and short-lived, so a quick-onset drug with short action is required. These pharmaceutical forms are transmucosal absorption (oral and nasal), since this route allows rapid absorption of the drug and high bioavailability. The pharmaceutical forms that achieve this rapid effect are: sucking tablets with integrated oral applicator, oral and sublingual tablets, oral films and intranasal preparations. It should be noted that these medications, although they contain the same active substance, have differences in their pharmacokinetic profiles, so they are not interchangeable. The forms of controlled release currently marketed are transdermal patches. These are used for the treatment of chronic or basal pain since they allow maintaining constant plasma levels of the drug.]]></p></abstract>
<kwd-group>
<kwd lng="es"><![CDATA[Fentanilo]]></kwd>
<kwd lng="es"><![CDATA[dolor irruptivo]]></kwd>
<kwd lng="es"><![CDATA[dolor crónico]]></kwd>
<kwd lng="es"><![CDATA[absorción transmucosa]]></kwd>
<kwd lng="es"><![CDATA[liberación inmediata]]></kwd>
<kwd lng="es"><![CDATA[liberación controlada]]></kwd>
<kwd lng="en"><![CDATA[Fentanyl]]></kwd>
<kwd lng="en"><![CDATA[breakthrough pain]]></kwd>
<kwd lng="en"><![CDATA[chronic pain]]></kwd>
<kwd lng="en"><![CDATA[transmucosal absorption]]></kwd>
<kwd lng="en"><![CDATA[immediate release]]></kwd>
<kwd lng="en"><![CDATA[delayed release]]></kwd>
</kwd-group>
</article-meta>
</front><back>
<ref-list>
<ref id="B1">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Harkouk]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Pares]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Daoudi]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Fletcher]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Farmacología de los opioides]]></article-title>
<source><![CDATA[EMC - Anestesia-Reanimación]]></source>
<year>2018</year>
<volume>44</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>1-24</page-range></nlm-citation>
</ref>
<ref id="B2">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Muriel]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[García-Castaño]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Yusta]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Sánchez-Montero]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Citrato de fentanilo transmucosa oral (OTFC): revisión]]></article-title>
<source><![CDATA[Rev Soc Esp Dolor]]></source>
<year>2000</year>
<volume>7</volume>
<page-range>319-26</page-range></nlm-citation>
</ref>
<ref id="B3">
<nlm-citation citation-type="">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Barral]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<source><![CDATA[Fentanilo: de analgésico a dolor de cabeza para el gobierno de EE.UU]]></source>
<year>2018</year>
</nlm-citation>
</ref>
<ref id="B4">
<nlm-citation citation-type="">
<collab>National Institute on Drug Abuse</collab>
<source><![CDATA[El fentanilo]]></source>
<year></year>
</nlm-citation>
</ref>
<ref id="B5">
<nlm-citation citation-type="">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Muriel]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Santos]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Sánchez-Montero]]></surname>
<given-names><![CDATA[FJ]]></given-names>
</name>
</person-group>
<source><![CDATA[Farmacología de los analgésicos opiáceos]]></source>
<year></year>
</nlm-citation>
</ref>
<ref id="B6">
<nlm-citation citation-type="">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Garzón-Rodríguez]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Farriols-Danés]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Rovira-Oliva]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Rodríguez-Trujillo]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Porta i Sales]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
</person-group>
<source><![CDATA[Guía práctica para el manejo del dolor irruptivo oncológico]]></source>
<year>2013</year>
</nlm-citation>
</ref>
<ref id="B7">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Álamo]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Zaragozá-Arnáez]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Noriega-Matanza]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Torres]]></surname>
<given-names><![CDATA[LM]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Fentanilo: una molécula y múltiples formulaciones galénicas de trascendencia clínica en el tratamiento del dolor irruptivo oncológico]]></article-title>
<source><![CDATA[Rev. Soc. Esp. Dolor]]></source>
<year>2017</year>
<volume>24</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>188-200</page-range></nlm-citation>
</ref>
<ref id="B8">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Decruynaere]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Bragard]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Evaluación del dolor: aspectos metodológicos y utilización en la clínica]]></article-title>
<source><![CDATA[EMC - Kinesiterapia - Medicina Física]]></source>
<year>2018</year>
<volume>39</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>1-14</page-range></nlm-citation>
</ref>
<ref id="B9">
<nlm-citation citation-type="">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Dopico-Santamariña]]></surname>
<given-names><![CDATA[LM]]></given-names>
</name>
<name>
<surname><![CDATA[Hermida-Porto]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
</person-group>
<source><![CDATA[Guía Clínica de manejo del dolor oncológico]]></source>
<year>2019</year>
</nlm-citation>
</ref>
<ref id="B10">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[García-Adrián]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Marrupe-González]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Barrio-Alonso]]></surname>
<given-names><![CDATA[MJ]]></given-names>
</name>
<name>
<surname><![CDATA[Vargas-Torres]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[García-Rodrigo]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Quibén-Pereira]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Diagnóstico: pautas diagnósticas y la adecuada gestión del dolor basal y del dolor irruptivo]]></article-title>
<source><![CDATA[Med. Paliat.]]></source>
<year>2015</year>
<volume>22</volume>
<page-range>10-4</page-range></nlm-citation>
</ref>
<ref id="B11">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Pernia]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Torres]]></surname>
<given-names><![CDATA[LM]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Tratamiento del dolor oncológico terminal intenso]]></article-title>
<source><![CDATA[Rev. Soc. Esp. Dolor]]></source>
<year>2008</year>
<volume>15</volume>
<numero>5</numero>
<issue>5</issue>
<page-range>308-24</page-range></nlm-citation>
</ref>
<ref id="B12">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Esparza-Miñana]]></surname>
<given-names><![CDATA[JM]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Diagnóstico y tratamiento médico del dolor irruptivo]]></article-title>
<source><![CDATA[Med. Clin]]></source>
<year>2018</year>
<volume>150</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>14-118</page-range></nlm-citation>
</ref>
<ref id="B13">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Portenoy]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Hagen]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Breakthrogh pain: definition, prevalence and characteristics]]></article-title>
<source><![CDATA[Pain]]></source>
<year>1990</year>
<volume>41</volume>
<page-range>273-81</page-range></nlm-citation>
</ref>
<ref id="B14">
<nlm-citation citation-type="">
<collab>Agencia Española del Medicamento y Productos Sanitarios</collab>
<source><![CDATA[CIMA: Centro de Información Online de Medicamentos de la AEMPS]]></source>
<year></year>
</nlm-citation>
</ref>
<ref id="B15">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Tormo-Ferrero]]></surname>
<given-names><![CDATA[V]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Vías de administración de fentanilo para el tratamiento del dolor irruptivo oncológico]]></article-title>
<source><![CDATA[Med. Paliat]]></source>
<year>2015</year>
<volume>22</volume>
<page-range>27-32</page-range></nlm-citation>
</ref>
<ref id="B16">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Mercadante]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Marchetti]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Cuomo]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Mammucari]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Caraceni]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Breakthrough pain and its treatment: critical review and recommendations of IOPS (Italian Oncologic Pain Survey) expert group]]></article-title>
<source><![CDATA[Support Care Cancer]]></source>
<year>2016</year>
<volume>24</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>961-8</page-range></nlm-citation>
</ref>
<ref id="B17">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Guo]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
<name>
<surname><![CDATA[Singh]]></surname>
<given-names><![CDATA[AP]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Emerging strategies for enhancing buccal and sublingual administration of nutraceuticals and pharamaceuticals]]></article-title>
<source><![CDATA[J. Drug Deliv. Sci. Technol]]></source>
<year>2019</year>
<volume>52</volume>
<page-range>440-51</page-range></nlm-citation>
</ref>
<ref id="B18">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Paredes-Mogollo]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Importancia de la vía nasal para la administración de opioides]]></article-title>
<source><![CDATA[Med Paliat]]></source>
<year>2015</year>
<volume>22</volume>
<page-range>33-45</page-range></nlm-citation>
</ref>
<ref id="B19">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Mercadante]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Prestia]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Adile]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Casuccio]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Intranasal fentanyl versus fentanyl pectin nasal spray for the management of breakthrough cancer pain in doses proportional to basal opioid regimen]]></article-title>
<source><![CDATA[The Journal of Pain]]></source>
<year>2014</year>
<volume>15</volume>
<numero>6</numero>
<issue>6</issue>
<page-range>602-7</page-range></nlm-citation>
</ref>
<ref id="B20">
<nlm-citation citation-type="">
<source><![CDATA[AEMPS: Fentanilo de liberación inmediata: importancia de respetar las condiciones de uso autorizadas]]></source>
<year>2018</year>
</nlm-citation>
</ref>
<ref id="B21">
<nlm-citation citation-type="">
<source><![CDATA[Real Farmacopea Española]]></source>
<year>2015</year>
</nlm-citation>
</ref>
<ref id="B22">
<nlm-citation citation-type="">
<collab>AEMPS</collab>
<source><![CDATA[Ficha Técnica de Actiq®]]></source>
<year></year>
</nlm-citation>
</ref>
<ref id="B23">
<nlm-citation citation-type="">
<collab>AEMPS</collab>
<source><![CDATA[Ficha Técnica de Abfentiq®]]></source>
<year></year>
</nlm-citation>
</ref>
<ref id="B24">
<nlm-citation citation-type="">
<source><![CDATA[Arydol: dolor irruptivo]]></source>
<year></year>
</nlm-citation>
</ref>
<ref id="B25">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[López]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Tovar]]></surname>
<given-names><![CDATA[I]]></given-names>
</name>
<name>
<surname><![CDATA[Romero]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Zurita]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Eficacia analgésica del citrato de fentanilo oral transmucosa en el dolor rectal irruptivo de pacientes oncológicos]]></article-title>
<source><![CDATA[Rev. Soc. Esp. Dolor]]></source>
<year>2010</year>
<volume>17</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>16-21</page-range></nlm-citation>
</ref>
<ref id="B26">
<nlm-citation citation-type="">
<collab>AEMPS</collab>
<source><![CDATA[Ficha Técnica de Effentora®]]></source>
<year></year>
</nlm-citation>
</ref>
<ref id="B27">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Mercadante]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Adile]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Cuomo]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Aielli]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Cortegiani]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Casuccio]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Fentanyl Buccal Tablet vs. Oral Morphine in Doses Proportional to the Basal Opioid Regimen for the Management of Breakthrough Cancer Pain: A Randomized, Crossover, Comparison Study]]></article-title>
<source><![CDATA[J. Pain Symptom. Manage.]]></source>
<year>2015</year>
<volume>50</volume>
<numero>5</numero>
<issue>5</issue>
<page-range>579-86</page-range></nlm-citation>
</ref>
<ref id="B28">
<nlm-citation citation-type="">
<source><![CDATA[Real Farmacopea Española]]></source>
<year>2015</year>
</nlm-citation>
</ref>
<ref id="B29">
<nlm-citation citation-type="">
<source><![CDATA[Ficha Técnica de Abstral®]]></source>
<year></year>
</nlm-citation>
</ref>
<ref id="B30">
<nlm-citation citation-type="">
<source><![CDATA[Ficha Técnica de Avaric®]]></source>
<year></year>
</nlm-citation>
</ref>
<ref id="B31">
<nlm-citation citation-type="">
<collab>AEMPS</collab>
<source><![CDATA[Guía para pacientes y cuidadores sobre el uso de Avaric®,]]></source>
<year>2015</year>
</nlm-citation>
</ref>
<ref id="B32">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Novotna]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Valentova]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Fricova]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Richterova]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Harabisova]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Bullier]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[A randomized, placebo-controlled study of a new sublingual formulation of fentanyl citrate (fentanyl ethypharm) for breakthrough pain in opioid-treated patients with cancer]]></article-title>
<source><![CDATA[Clin Ther]]></source>
<year>2014</year>
<volume>36</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>357-67</page-range></nlm-citation>
</ref>
<ref id="B33">
<nlm-citation citation-type="">
<source><![CDATA[Ficha Técnica de Breakyl®]]></source>
<year></year>
</nlm-citation>
</ref>
<ref id="B34">
<nlm-citation citation-type="">
<source><![CDATA[Breakyl® película bucal. Información sobre prevención de riesgos autorizada por la Agencia Española de Medicamentos y Productos Sanitarios (AEMPS)]]></source>
<year>2018</year>
</nlm-citation>
</ref>
<ref id="B35">
<nlm-citation citation-type="">
<source><![CDATA[Real Farmacopea Española]]></source>
<year>2015</year>
</nlm-citation>
</ref>
<ref id="B36">
<nlm-citation citation-type="">
<collab>AEMPS</collab>
<source><![CDATA[Ficha Técnica de Instanyl®]]></source>
<year></year>
</nlm-citation>
</ref>
<ref id="B37">
<nlm-citation citation-type="">
<collab>AEMPS</collab>
<source><![CDATA[Ficha Técnica de PecFent®]]></source>
<year></year>
</nlm-citation>
</ref>
<ref id="B38">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Schug]]></surname>
<given-names><![CDATA[SA]]></given-names>
</name>
<name>
<surname><![CDATA[Ting]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Fentanyl Formulations in the Management of Pain: An Update]]></article-title>
<source><![CDATA[Drugs]]></source>
<year>2017</year>
<volume>77</volume>
<numero>7</numero>
<issue>7</issue>
<page-range>747-63</page-range></nlm-citation>
</ref>
<ref id="B39">
<nlm-citation citation-type="">
<source><![CDATA[Actiq/Abstral/Effentora: Tratamiento del dolor irruptivo en pacientes con dolor crónico por cáncer. Informe de la Comisión de Farmacia y Terapéutica del Instituto Catalán de Oncología]]></source>
<year>2010</year>
</nlm-citation>
</ref>
<ref id="B40">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Smith]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[A comprehensive review of rapid-onset opioids for breakthrough pain]]></article-title>
<source><![CDATA[CNS Drugs]]></source>
<year>2012</year>
<volume>26</volume>
<numero>6</numero>
<issue>6</issue>
<page-range>509-35</page-range></nlm-citation>
</ref>
<ref id="B41">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Jandhyala]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Fullarton]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Various formulations of oral transmucosal fentanyl for breakthrough cancer pain: An indirect mixed treatment comparison meta-analysis]]></article-title>
<source><![CDATA[BMJ Supportive &amp; Palliative Care]]></source>
<year>2012</year>
<volume>2</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>156-62</page-range></nlm-citation>
</ref>
<ref id="B42">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[López-Mongil]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Moreno-Villajos]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
<name>
<surname><![CDATA[Escudero-Andrés]]></surname>
<given-names><![CDATA[JM]]></given-names>
</name>
<name>
<surname><![CDATA[Tellaeche]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Achón y Tuñón M. Patologías del Envejecimiento: El dolor como gran síndrome geriátrico (II)]]></article-title>
<source><![CDATA[Aula de la Farmacia]]></source>
<year>2019</year>
<volume>15</volume>
<numero>130</numero>
<issue>130</issue>
<page-range>9-18</page-range></nlm-citation>
</ref>
<ref id="B43">
<nlm-citation citation-type="">
<source><![CDATA[Real Farmacopea Española]]></source>
<year>2015</year>
</nlm-citation>
</ref>
<ref id="B44">
<nlm-citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Llovet i Traveset]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
</person-group>
<source><![CDATA[Parches transdérmicos]]></source>
<year></year>
<publisher-name><![CDATA[Centro de Información de Medicamentos de Cataluña]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B45">
<nlm-citation citation-type="">
<source><![CDATA[Proyecto REDES: Manejo del dolor con opioides]]></source>
<year></year>
</nlm-citation>
</ref>
<ref id="B46">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[García Quetglas]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Azanza Perea]]></surname>
<given-names><![CDATA[JR]]></given-names>
</name>
<name>
<surname><![CDATA[Rada]]></surname>
<given-names><![CDATA[Sádaba Díaz de]]></given-names>
</name>
<name>
<surname><![CDATA[Campanero Martínez]]></surname>
<given-names><![CDATA[MA]]></given-names>
</name>
<name>
<surname><![CDATA[Urdaneta Abate]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Fentanilo. Sistema terapéutico transdérmico y características de las distintas formulaciones]]></article-title>
<source><![CDATA[Dolor]]></source>
<year>2007</year>
<volume>22</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>195-205</page-range></nlm-citation>
</ref>
<ref id="B47">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Torres]]></surname>
<given-names><![CDATA[LM]]></given-names>
</name>
<name>
<surname><![CDATA[Collado]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Martínez-Vázquez de Castro]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Calderón]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Sánchez-Pardo]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Molano]]></surname>
<given-names><![CDATA[JL]]></given-names>
</name>
<name>
<surname><![CDATA[del Álamo]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Efectos de la intercambiabilidad de fentanilo transdérmico]]></article-title>
<source><![CDATA[Rev. Soc. Esp. Dolor]]></source>
<year>2009</year>
<volume>16</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>21-8</page-range></nlm-citation>
</ref>
<ref id="B48">
<nlm-citation citation-type="">
<collab>AEMPS</collab>
<source><![CDATA[Ficha Técnica de Fentanilo Matrix Cinfa]]></source>
<year></year>
</nlm-citation>
</ref>
<ref id="B49">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Torres]]></surname>
<given-names><![CDATA[LM]]></given-names>
</name>
<name>
<surname><![CDATA[Calderón]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Rey]]></surname>
<given-names><![CDATA[RM]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Fentanilo transdérmico (Durogesic®): características farmacológicas y aplicación clínica]]></article-title>
<source><![CDATA[Rev. Soc. Esp. Dolor]]></source>
<year>1999</year>
<volume>6</volume>
<page-range>121-31</page-range></nlm-citation>
</ref>
<ref id="B50">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Navarro Ruiz]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Borrás Blasco]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Martínez Ramírez]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[González Delgado]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Sistema de liberación transdérmico de fentanilo: una nueva forma de analgesia oncológica]]></article-title>
<source><![CDATA[Farm Hosp]]></source>
<year>2000</year>
<volume>24</volume>
<page-range>64-73</page-range></nlm-citation>
</ref>
<ref id="B51">
<nlm-citation citation-type="book">
<collab>Agencia Española de Medicamentos y Productos Sanitarios</collab>
<source><![CDATA[Utilización de medicamentos opioides en España durante el periodo 2008-2015]]></source>
<year>2017</year>
<publisher-loc><![CDATA[Madrid ]]></publisher-loc>
<publisher-name><![CDATA[AEMPS]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B52">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Fernández Hernández]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Bouzas Pérez]]></surname>
<given-names><![CDATA[D.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Fentanilo de liberación rápida: la punta del iceberg]]></article-title>
<source><![CDATA[Rev. Soc. Esp. Dolor]]></source>
<year>2017</year>
<volume>25</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>62-3</page-range></nlm-citation>
</ref>
<ref id="B53">
<nlm-citation citation-type="">
<collab>Farmacia de Atención Primaria</collab>
<source><![CDATA[Riesgo de adicción a fentanilo transmucoso, un problema a tener en cuenta]]></source>
<year></year>
</nlm-citation>
</ref>
<ref id="B54">
<nlm-citation citation-type="">
<collab>Sociedad Española del Dolor. Grupo de trabajo de opioides</collab>
<source><![CDATA[Jornadas de actualización en el manejo de opioides]]></source>
<year></year>
</nlm-citation>
</ref>
</ref-list>
</back>
</article>
